NBIX logo

Neurocrine Biosciences (NBIX) Cash From Operations

Annual CFO

$389.90 M
+$50.50 M+14.88%

31 December 2023

NBIX Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFO

$158.00 M
+$93.40 M+144.58%

30 September 2024

NBIX Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFO

$476.40 M
-$54.00 M-10.18%

30 September 2024

NBIX TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NBIX Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+14.9%-25.5%+16.4%
3 y3 years+70.6%+155.7%+37.4%
5 y5 years+284.5%+61.5%+376.4%

NBIX Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+70.6%-25.5%+226.2%-26.2%+270.2%
5 y5 yearsat high+284.5%-25.5%+226.2%-26.2%+376.4%
alltimeall timeat high+467.2%-25.5%+226.2%-26.2%+353.1%

Neurocrine Biosciences Cash From Operations History

DateAnnualQuarterlyTTM
Sept 2024
-
$158.00 M(+144.6%)
$476.40 M(-10.2%)
June 2024
-
$64.60 M(-50.4%)
$530.40 M(-17.8%)
Mar 2024
-
$130.30 M(+5.5%)
$645.40 M(+65.5%)
Dec 2023
$389.90 M(+14.9%)
$123.50 M(-41.7%)
$389.90 M(-4.8%)
Sept 2023
-
$212.00 M(+18.0%)
$409.40 M(+38.2%)
June 2023
-
$179.60 M(-243.5%)
$296.20 M(+16.3%)
Mar 2023
-
-$125.20 M(-187.6%)
$254.70 M(-25.0%)
Dec 2022
$339.40 M(+32.3%)
$143.00 M(+44.7%)
$339.40 M(+69.2%)
Sept 2022
-
$98.80 M(-28.5%)
$200.60 M(+22.6%)
June 2022
-
$138.10 M(-441.0%)
$163.60 M(+27.1%)
Mar 2022
-
-$40.50 M(-1064.3%)
$128.70 M(-49.8%)
Dec 2021
$256.50 M(+12.3%)
$4.20 M(-93.2%)
$256.50 M(-26.0%)
Sept 2021
-
$61.80 M(-40.1%)
$346.80 M(+31.1%)
June 2021
-
$103.20 M(+18.2%)
$264.60 M(-5.6%)
Mar 2021
-
$87.30 M(-7.6%)
$280.30 M(+22.7%)
Dec 2020
$228.50 M(+55.4%)
$94.50 M(-563.2%)
$228.50 M(-1.3%)
Sept 2020
-
-$20.40 M(-117.2%)
$231.50 M(-33.8%)
June 2020
-
$118.90 M(+234.9%)
$349.70 M(+18.5%)
Mar 2020
-
$35.50 M(-63.6%)
$295.00 M(+100.7%)
Dec 2019
$147.00 M(+45.0%)
$97.50 M(-0.3%)
$147.00 M(+47.0%)
Sept 2019
-
$97.80 M(+52.3%)
$99.99 M(+40.6%)
June 2019
-
$64.20 M(-157.1%)
$71.11 M(+159.6%)
Mar 2019
-
-$112.50 M(-322.8%)
$27.39 M(-73.0%)
Dec 2018
$101.40 M(-207.5%)
$50.49 M(-26.7%)
$101.40 M(+10.8%)
Sept 2018
-
$68.92 M(+236.5%)
$91.48 M(+590.0%)
June 2018
-
$20.48 M(-153.2%)
$13.26 M(-123.9%)
Mar 2018
-
-$38.49 M(-194.9%)
-$55.46 M(-41.2%)
Dec 2017
-$94.33 M(-11.2%)
$40.58 M(-535.8%)
-$94.33 M(-43.4%)
Sept 2017
-
-$9.31 M(-80.7%)
-$166.53 M(-11.5%)
June 2017
-
-$48.24 M(-37.6%)
-$188.23 M(+22.0%)
Mar 2017
-
-$77.36 M(+144.6%)
-$154.33 M(+45.3%)
Dec 2016
-$106.18 M(+179.4%)
-$31.63 M(+2.0%)
-$106.18 M(+18.3%)
Sept 2016
-
-$31.01 M(+116.3%)
-$89.76 M(+16.1%)
June 2016
-
-$14.34 M(-50.9%)
-$77.32 M(+57.7%)
Mar 2016
-
-$29.21 M(+92.1%)
-$49.02 M(+29.0%)
Dec 2015
-$38.00 M(-19.4%)
-$15.20 M(-18.1%)
-$38.00 M(-0.3%)
Sept 2015
-
-$18.57 M(-233.0%)
-$38.10 M(+20.5%)
June 2015
-
$13.96 M(-176.8%)
-$31.63 M(-43.1%)
Mar 2015
-
-$18.18 M(+18.8%)
-$55.56 M(+17.9%)
Dec 2014
-$47.14 M(+59.2%)
-$15.31 M(+26.5%)
-$47.14 M(+10.4%)
Sept 2014
-
-$12.10 M(+21.4%)
-$42.71 M(+3.2%)
June 2014
-
-$9.96 M(+2.0%)
-$41.39 M(+0.3%)
Mar 2014
-
-$9.77 M(-10.2%)
-$41.29 M(+39.4%)
Dec 2013
-$29.61 M(-16.1%)
-$10.88 M(+0.9%)
-$29.61 M(+7.1%)
Sept 2013
-
-$10.78 M(+9.3%)
-$27.64 M(+9.8%)
June 2013
-
-$9.86 M(-615.7%)
-$25.16 M(+13.4%)
Mar 2013
-
$1.91 M(-121.5%)
-$22.18 M(-37.2%)
Dec 2012
-$35.29 M(+4956.4%)
-$8.91 M(+7.3%)
-$35.29 M(+129.7%)
Sept 2012
-
-$8.30 M(+20.7%)
-$15.37 M(+258.2%)
June 2012
-
-$6.88 M(-38.6%)
-$4.29 M(+29.1%)
Mar 2012
-
-$11.20 M(-201.7%)
-$3.32 M(+375.9%)
Dec 2011
-$698.00 K(-101.4%)
$11.02 M(+297.5%)
-$698.00 K(-95.7%)
Sept 2011
-
$2.77 M(-146.9%)
-$16.25 M(-9.1%)
June 2011
-
-$5.91 M(-31.1%)
-$17.88 M(-133.4%)
Mar 2011
-
-$8.58 M(+89.5%)
$53.55 M(+7.2%)
Dec 2010
$49.94 M
-$4.53 M(-496.8%)
$49.94 M(+23.3%)
Sept 2010
-
$1.14 M(-98.3%)
$40.50 M(+43.3%)
DateAnnualQuarterlyTTM
June 2010
-
$65.52 M(-637.6%)
$28.26 M(-155.5%)
Mar 2010
-
-$12.19 M(-12.8%)
-$50.89 M(-4.1%)
Dec 2009
-$53.09 M(-28.4%)
-$13.97 M(+25.9%)
-$53.09 M(-4.2%)
Sept 2009
-
-$11.10 M(-18.6%)
-$55.41 M(-6.1%)
June 2009
-
-$13.63 M(-5.3%)
-$59.01 M(-2.3%)
Mar 2009
-
-$14.39 M(-11.7%)
-$60.39 M(-18.6%)
Dec 2008
-$74.17 M(+25.0%)
-$16.29 M(+10.9%)
-$74.17 M(+19.4%)
Sept 2008
-
-$14.70 M(-2.1%)
-$62.10 M(-9.9%)
June 2008
-
-$15.01 M(-46.7%)
-$68.91 M(-5.2%)
Mar 2008
-
-$28.17 M(+566.5%)
-$72.65 M(+22.4%)
Dec 2007
-$59.33 M(-40.3%)
-$4.23 M(-80.3%)
-$59.33 M(-17.5%)
Sept 2007
-
-$21.50 M(+14.6%)
-$71.91 M(-14.5%)
June 2007
-
-$18.75 M(+26.3%)
-$84.15 M(-10.3%)
Mar 2007
-
-$14.85 M(-11.6%)
-$93.84 M(-5.5%)
Dec 2006
-$99.33 M(+222.6%)
-$16.80 M(-50.2%)
-$99.33 M(-5.8%)
Sept 2006
-
-$33.74 M(+18.6%)
-$105.44 M(+304.0%)
June 2006
-
-$28.44 M(+39.8%)
-$26.10 M(+3.7%)
Mar 2006
-
-$20.35 M(-11.2%)
-$25.16 M(-18.3%)
Dec 2005
-$30.79 M(-69.2%)
-$22.90 M(-150.2%)
-$30.79 M(-16.7%)
Sept 2005
-
$45.60 M(-265.8%)
-$36.95 M(-58.7%)
June 2005
-
-$27.51 M(+5.9%)
-$89.43 M(-11.9%)
Mar 2005
-
-$25.98 M(-10.6%)
-$101.47 M(+1.5%)
Dec 2004
-$99.99 M(-369.3%)
-$29.06 M(+322.0%)
-$99.99 M(+37.8%)
Sept 2004
-
-$6.88 M(-82.6%)
-$72.57 M(+0.7%)
June 2004
-
-$39.55 M(+61.5%)
-$72.06 M(+43.6%)
Mar 2004
-
-$24.49 M(+1391.6%)
-$50.18 M(-235.2%)
Dec 2003
$37.13 M(-146.8%)
-$1.64 M(-74.2%)
$37.13 M(+520.6%)
Sept 2003
-
-$6.38 M(-63.9%)
$5.98 M(-354.9%)
June 2003
-
-$17.67 M(-128.1%)
-$2.35 M(-47.3%)
Mar 2003
-
$62.82 M(-291.6%)
-$4.45 M(-94.4%)
Dec 2002
-$79.36 M(+263.1%)
-$32.79 M(+123.0%)
-$79.36 M(+70.7%)
Sept 2002
-
-$14.71 M(-25.7%)
-$46.49 M(+40.5%)
June 2002
-
-$19.78 M(+63.6%)
-$33.09 M(+28.6%)
Mar 2002
-
-$12.09 M(<-9900.0%)
-$25.73 M(+17.7%)
Dec 2001
-$21.86 M(+17.2%)
$91.00 K(-107.0%)
-$21.86 M(-21.3%)
Sept 2001
-
-$1.30 M(-89.5%)
-$27.77 M(-2.6%)
June 2001
-
-$12.43 M(+51.2%)
-$28.52 M(+14.6%)
Mar 2001
-
-$8.22 M(+41.2%)
-$24.90 M(+33.5%)
Dec 2000
-$18.64 M(+81.0%)
-$5.82 M(+183.3%)
-$18.64 M(+73.9%)
Sept 2000
-
-$2.06 M(-76.7%)
-$10.72 M(-14.0%)
June 2000
-
-$8.80 M(+348.0%)
-$12.47 M(+50.9%)
Mar 2000
-
-$1.97 M(-193.6%)
-$8.27 M(-19.8%)
Dec 1999
-$10.30 M(-3.7%)
$2.10 M(-155.3%)
-$10.30 M(-31.8%)
Sept 1999
-
-$3.80 M(-17.4%)
-$15.10 M(+31.3%)
June 1999
-
-$4.60 M(+15.0%)
-$11.50 M(+27.8%)
Mar 1999
-
-$4.00 M(+48.1%)
-$9.00 M(-15.9%)
Dec 1998
-$10.70 M(-197.3%)
-$2.70 M(+1250.0%)
-$10.70 M(-813.3%)
Sept 1998
-
-$200.00 K(-90.5%)
$1.50 M(-78.6%)
June 1998
-
-$2.10 M(-63.2%)
$7.00 M(+133.3%)
Mar 1998
-
-$5.70 M(-160.0%)
$3.00 M(-72.7%)
Dec 1997
$11.00 M(+64.2%)
$9.50 M(+79.2%)
$11.00 M(-4.3%)
Sept 1997
-
$5.30 M(-186.9%)
$11.50 M(+105.4%)
June 1997
-
-$6.10 M(-365.2%)
$5.60 M(-51.7%)
Mar 1997
-
$2.30 M(-77.0%)
$11.60 M(+73.1%)
Dec 1996
$6.70 M
$10.00 M(-1766.7%)
$6.70 M(-303.0%)
Sept 1996
-
-$600.00 K(+500.0%)
-$3.30 M(+22.2%)
June 1996
-
-$100.00 K(-96.2%)
-$2.70 M(+3.8%)
Mar 1996
-
-$2.60 M
-$2.60 M

FAQ

  • What is Neurocrine Biosciences annual cash flow from operations?
  • What is the all time high annual CFO for Neurocrine Biosciences?
  • What is Neurocrine Biosciences annual CFO year-on-year change?
  • What is Neurocrine Biosciences quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Neurocrine Biosciences?
  • What is Neurocrine Biosciences quarterly CFO year-on-year change?
  • What is Neurocrine Biosciences TTM cash flow from operations?
  • What is the all time high TTM CFO for Neurocrine Biosciences?
  • What is Neurocrine Biosciences TTM CFO year-on-year change?

What is Neurocrine Biosciences annual cash flow from operations?

The current annual CFO of NBIX is $389.90 M

What is the all time high annual CFO for Neurocrine Biosciences?

Neurocrine Biosciences all-time high annual cash flow from operations is $389.90 M

What is Neurocrine Biosciences annual CFO year-on-year change?

Over the past year, NBIX annual cash flow from operations has changed by +$50.50 M (+14.88%)

What is Neurocrine Biosciences quarterly cash flow from operations?

The current quarterly CFO of NBIX is $158.00 M

What is the all time high quarterly CFO for Neurocrine Biosciences?

Neurocrine Biosciences all-time high quarterly cash flow from operations is $212.00 M

What is Neurocrine Biosciences quarterly CFO year-on-year change?

Over the past year, NBIX quarterly cash flow from operations has changed by -$54.00 M (-25.47%)

What is Neurocrine Biosciences TTM cash flow from operations?

The current TTM CFO of NBIX is $476.40 M

What is the all time high TTM CFO for Neurocrine Biosciences?

Neurocrine Biosciences all-time high TTM cash flow from operations is $645.40 M

What is Neurocrine Biosciences TTM CFO year-on-year change?

Over the past year, NBIX TTM cash flow from operations has changed by +$67.00 M (+16.37%)